Akamis Bio Limited Announces Executive Appointments

Akamis Bio announced the appointment of Oliver Rosen as Chief Medical Officer (CMO), Peter Kosa as Chief Business Officer (CBO), and Samantha Bailey-Bucktrout as Senior Vice President, Head of Research.

Dr. Oliver Rosen most recently served as President and CMO at DynamiCure and brings extensive experience in drug development. As CMO at Akamis Bio, he will lead the clinical development and regulatory strategy, leveraging his expertise in advancing novel therapies.

Peter Kosa will be overseeing corporate strategy, business development, and partnerships. With a background in venture capital and strategic alliances, Dr. Peter has held leadership positions at organizations such as the Myeloma Investment Fund, bluebird bio, and Novartis Institutes for Biomedical Research.

Dr. Samantha Bailey-Bucktrout, joined Akamis Bio as Vice President of Research Strategy. In this role, she will lead the company’s discovery and preclinical programs.

Akamis Bio is a biopharmaceutical company focused on developing innovative therapies in the field of oncology and immunology.